Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Expression analysis in a rat psychosis model identifies novel candidate genes validated in a large case-control sample of schizophrenia.

Authors: Ingason, A  Giegling, I  Hartmann, AM  Genius, J  Konte, B  Friedl, M  Ripke, S  Sullivan, PF  St Clair, D  Collier, DA  O'Donovan, MC  Mirnics, K  Rujescu, D  Rujescu, D 
Citation: Ingason A, etal., Transl Psychiatry. 2015 Oct 13;5:e656. doi: 10.1038/tp.2015.151.
Pubmed: (View Article at PubMed) PMID:26460480
DOI: Full-text: DOI:10.1038/tp.2015.151

Antagonists of the N-methyl-D-aspartate (NMDA)-type glutamate receptor induce psychosis in healthy individuals and exacerbate schizophrenia symptoms in patients. In this study we have produced an animal model of NMDA receptor hypofunction by chronically treating rats with low doses of the NMDA receptor antagonist MK-801. Subsequently, we performed an expression study and identified 20 genes showing altered expression in the brain of these rats compared with untreated animals. We then explored whether the human orthologs of these genes are associated with schizophrenia in the largest schizophrenia genome-wide association study published to date, and found evidence for association for 4 out of the 20 genes: SF3B1, FOXP1, DLG2 and VGLL4. Interestingly, three of these genes, FOXP1, SF3B1 and DLG2, have previously been implicated in neurodevelopmental disorders.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 11353286
Created: 2016-07-20
Species: All species
Last Modified: 2016-07-20
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.